Methotrexate is a disease-modifying antirheumatic drug (DMAR…
Methotrexate is a disease-modifying antirheumatic drug (DMARD) that is an antimetabolite chemotherapeutic agent. The drug is a folic acid antagonist that interferes with DNA synthesis and repair mechanisms. Tissues that are metabolically active are more sensitive to the effects of the medication. Serum levels peak at 1-2 hours after ingestion and 30-60 minutes after intramuscular injection. Prolonged effects of the medication can be seen in patients with ascites or other effusions since the medication accumulates in the third-space fluid. This drug is commonly used in the treatment of inflammatory arthritis, including rheumatoid arthritis and other autoimmune diseases. When methotrexate is used long-term, it has been associated with the development of elevations in liver aminotransferase levels, chronic liver injury, fibrosis of the liver, and cirrhosis. When administered in high intravenous doses, the drug may cause acute elevations of liver enzymes. Minor elevation of liver enzymes is common in patients who are taking methotrexate, but hepatotoxicity can occur. Liver aminotransferase levels and kidney function should be evaluated prior to starting therapy and monitored while taking the medication. Patients should be monitored for side effects, including stomatitis, gastrointestinal upset, alopecia, symptoms of myelosuppression, hepatotoxicity, and infection while taking methotrexate. In addition, patients should not become pregnant while taking methotrexate as this is a teratogenic and embryotoxic drug.
Read DetailsThe NCSBN Clinical Judgment Measurement Model (NCSBN-CJMM) c…
The NCSBN Clinical Judgment Measurement Model (NCSBN-CJMM) contains six clearly defined steps, with each one identifying a thought process integral to making sound clinical judgments/decisions. The nurse identifies which question to be an example of the step of analyzing cues?
Read Details